安维汀控制肿瘤生长.pptVIP

Introduction Angiogenesis is one of the essential requirements for the growth and development of all tumour types1 the anti-angiogenic monoclonal antibody Avastin has demonstrated clinical efficacy in a range of different tumour types2–5 Avastin can be combined safely and effectively with both chemotherapy and immunotherapy2–5 ? Continuous expression of VEGF throughout the tumour life cycle validates the use of Avastin up to tumour progression this is supported by data from Avastin clinical trials6,7 Precise VEGF inhibition by Avastin limits its toxicity8 Avastin used as first-line therapy provides benefit in?several tumour types First-line use of Avastin extends OS and/or PFS across multiple tumour types1–5 Avastin is indicated in Europe and the USA for use in the treatment of mCRC mBC unresectable advanced, metastatic or recurrent NSCLC advanced and/or metastatic RCC1,6 in the USA for the treatment of GBM as a single agent for patients with progressive disease following prior therapy6 Comprehensive Avastin biomarker programme ongoing Clinical trial data* currently support the use of Avastin in unselected patients in the absence of a predictive biomarker1–8 Candidate Avastin biomarkers have been tested in several indications A validated predictive biomarker for Avastin has not yet been identified, although several promising candidates have been investigated Potential biomarkers in samples from phase III studies of Avastin in mCRC, advanced NSCLC and mBC have been tested for correlation with outcome1–6 many of these analyses had low power due to the small sample sizes involved1–6 Avastin benefits all patient subgroups in phase III trials across indications mCRC: OS benefit was observed in all patient subgroups, independent of baseline risk factors such as performance status, number of metastatic sites and adjuvant chemotherapy1 mNSCLC: all patient subgroups benefited in a phase III study in non-squamous NSCLC2 in an E4599 study subgroup analysis, first-